Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122:2044–52.
2. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do D V, Midena E, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016;123:2376–85. https://pubmed-ncbi-nlm-nih-gov.login.ezproxy.library.ualberta.ca/27651226/. Accessed 27 Dec 2021.
3. Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet (London, England). 2017;389:2193–203. https://pubmed-ncbi-nlm-nih-gov.login.ezproxy.library.ualberta.ca/28494920/. Accessed 27 Dec 2021.
4. Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314:2137. https://doi.org/10.1001/jama.2015.15217. Accessed 27 Dec 2021.
5. Sun JK, Glassman AR, Beaulieu WT, Stockdale CR, Bressler NM, Flaxel C, et al. Rationale and application of the protocol s anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy. Ophthalmology. 2019;126:87. https://doi.org/10.1016/j.ophtha.2018.08.001. Accessed 27 Dec 2021.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献